

Expert Speak

Decoding impact of US tariffs on Indian pharma

Tariffs may increase the cost of medicines for US patient pool

We hosted Mr. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA), and Ms. Archana Jatkar, Associate Secretary General, IPA, to understand the way forward for the Indian pharmaceutical industry after the announcement of tariffs on pharm imports by the US. Here are the key takeaways from this session:

- The reciprocal tariffs would have a minimal impact on India pharma exports, as India has an export surplus of medicines to the US.
- While US President Donald Trump is expected to make a detailed announcement on 2nd Apr'25, there is work-in-progress for a bilateral trade agreement.
- The price erosion of 10-11% annually has already reduced the cost of medicines for the US patient pool. The impact of the tariffs, when implemented, would be passed on to patients, thereby increasing the cost of medicine.
- Government of India has implemented schemes like PLI to promote indigenous manufacturing.
- India pharma products account for ~44% of the US pharma market by volume and 47% of generics prescriptions. Thus, it would be difficult to replace Indian pharma manufacturers purely by a tariff increase.

Apart from the above, following are the key takeaways:

- India's total medicine exports stand at USD28b, of which the US accounts for USD8.7b FY24. India imports medicines worth nearly USD800m from the US. Last year, India reduced import duties on oncology products worth USD200m and this year, it is estimated to cut duties on a few more oncology products worth USD300-400m. **Based on these estimates, the potential impact of a reciprocal tariff reduction is expected to be low.**
- India – U.S. joint statement during the visit of Prime Minister of India to US sets a goal for bilateral trade “Mission 500” aiming to more than double total bilateral trade to USD500b by 2030. They also announced plans to negotiate the first tranche of a multi-sector bilateral trade agreement (BTA) by fall of CY25. The proposal regarding reciprocal tariffs is currently under discussions, and further steps will be determined accordingly.
- About 90% of the US patient prescriptions are filled with generics medicines, and these medicines accounted for ~15% of the total invoice spending on all medicines last year.
- In terms of prescriptions, Indian pharma companies supply a substantial proportion of drugs to US residents, with three out of 10 prescriptions filled in the US being supplied by Indian companies. In particular, Indian companies supply 47% of all generics prescriptions filed in the US and 15% of the volume of biosimilars. The top 23 companies (part of IPA) form 80% of generics exports from India. India's cost of manufacturing drugs is about 20-30% of that in US, providing US residents access to affordable medicines. Thus, India plays a critical role in supplying medicines that enhance patient access, improve management of health conditions, and lead to savings and sustainability in the overall health system. Overall, generic drugs saved the US health system an estimated USD408b in CY22 and nearly USD2.9t over the last 10 years.



Mr. Sudarshan Jain
(Secretary General, IPA)

Mr. Jain has a rich healthcare business experience of over 45 years and has contributed to shaping healthcare policy and improving access to healthcare in India. He has held several leadership positions in Abbott, J&J, Boots and leading Indian companies.



Ms. Archana Jatkar
(Associate Secretary General, IPA)

She oversees international trade and global affairs with a focus on developing and executing strategic approaches for the Indian pharma sector, both domestically and internationally. Ms. Jatkar currently holds the position of Chair for the International Trade and Intellectual Property Committee of the International Generic and Biosimilar Association.

- **The price erosion of 10-11% annually over the past few years in the generics segment has been reducing the cost burden on US patients.**
- Several factors, such as the consolidation of group purchasing organizations, pharmacy benefit managers (PBMs), and low pricing, are impacting the supply of certain critical medicines that are economically unviable, driving drug shortages in the US.
- The implementation of tariffs is likely to increase the cost of medicines to US patients given the cost of manufacturing and maintaining compliance standards.
- De-risking the affordable medicine supply chain is crucial for both India and the US, particularly in addressing the risks associated with dependence on single-source suppliers like China for APIs and KSMs. India's initiatives (e.g., PLI scheme) since 2020 to boost API and KSM production have now started yielding results by augmenting the capacity to produce essential medications domestically such as Penicillin G.
- Apart from India, the US procures medicines from Ireland, Germany, Switzerland, Japan, Canada, China and other European countries.
- **The proposal regarding reciprocal tariffs will be discussed through bilateral engagements between the two countries, and further steps will be determined accordingly. If implemented, PBMs may be forced to take the hit of tariff increases.**


Exhibit 1: Valuation table

Company	Reco	MCAp (USDb)	EPS (INR)			EPS Gr. YoY (%)		PE (x)		EV/EBITDA (x)		ROE (%)		
			FY25E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	FY25E	FY26E	FY27E
Ajanta Pharma	Buy	4.7	62.3	75.8	88.1	21.7	16.0	40.9	35.2	29.0	25.1	22.7	24.5	23.8
Alembic Pharma	Neutral	2.6	31.5	37.6	41.5	19.7	10.3	31.0	28.1	18.8	16.8	13.5	14.3	13.9
Alkem Lab	Neutral	8.6	159.7	178.1	202.9	11.6	13.9	33.6	29.5	28.6	24.8	19.7	19.1	18.8
Aurobindo Pharma	Neutral	10.4	56.0	66.3	73.8	18.3	11.3	22.3	20.1	11.8	10.8	11.6	12.3	12.2
Biocon	Neutral	5.3	1.8	5.0	10.4	180.0	106.1	73.4	35.6	16.5	12.8	1.1	3.0	5.9
Cipla	Buy	16.0	52.5	58.7	65.6	11.9	11.7	28.2	25.3	18.4	16.1	15.9	15.4	14.9
Divi's Lab.	Neutral	17.1	60.0	77.7	95.1	29.6	22.4	69.1	56.5	48.5	40.4	12.1	14.4	15.9
Dr Reddy's Labs	Neutral	13.3	317.1	353.8	389.0	11.6	9.9	18.8	17.1	11.1	9.3	20.7	19.1	17.7
Eris Lifescience	Neutral	2.2	29.2	30.4	42.0	4.0	38.0	43.5	31.5	16.8	14.6	16.8	15.2	18.2
Gland Pharma	Buy	3.6	47.6	56.1	67.8	17.8	20.9	32.9	27.2	18.5	15.4	9.4	10.1	10.9
Glenmark Pharma	Buy	5.8	2.5	47.5	59.2	1812.8	24.6	36.0	28.9	18.9	15.7	0.8	15.8	16.8
Glaxosmit Pharma	Neutral	5.5	43.3	47.3	51.5	9.2	8.9	57.6	52.9	43.1	39.1	41.3	38.0	34.7
Granules India	Buy	1.6	17.4	24.0	31.9	38.5	32.5	23.3	17.6	13.3	10.8	13.9	16.6	18.6
Ipca Labs.	Buy	4.4	20.8	33.5	44.4	61.3	32.6	43.4	32.8	22.9	19.2	8.7	12.7	15.0
Laurus Labs	Buy	3.0	3.0	7.2	12.9	139.9	78.2	65.5	36.8	24.5	18.6	4.0	9.1	14.7
Lupin	Neutral	11.8	41.5	59.2	69.9	42.4	18.2	36.9	31.2	21.6	18.2	14.1	17.3	17.4
Mankind Pharma	Buy	12.7	47.8	54.5	62.4	14.1	14.6	48.7	42.5	34.3	29.2	22.8	21.4	20.9
Piramal Pharma	Buy	3.5	0.4	2.5	5.1	497.1	103.1	87.6	43.1	22.3	16.9	0.8	4.1	7.9
Sun Pharma.Inds.	Buy	53.5	41.4	49.3	58.4	19.1	18.4	37.7	31.9	30.0	25.5	16.7	17.3	17.6
Torrent Pharma.	Neutral	14.0	47.1	63.4	82.0	34.6	29.3	54.5	42.2	29.3	24.5	24.4	28.5	30.5
Zydus LifeScience	Neutral	12.7	37.6	43.9	47.3	16.5	7.9	24.1	22.3	15.9	14.3	20.3	19.6	17.4


Source: MOFSL, Company

India dominates the US generic market

- The US pharma market has registered a 10% CAGR over FY19-24, reaching USD753b.
- Of the total pharma market, generic products account for ~11% (~USD84b) and innovative products account for the rest (USD669b).
- Of the prescriptions generated in the US market, generic drugs make up 90%, and India accounts for 47% of generic sales in the US market.


Exhibit 2: US pharma market registered 10% CAGR over FY19-24

Source: MOFSL, Rubicon DRHP


Exhibit 3: Generic market accounts for 11% of total US Pharma market by value

Source: MOFSL, Rubicon DRHP

- As of CY23, US imported ~USD82.7b of packaged medicaments. The top 5 countries that export to the US are Ireland (16%), Switzerland (13%), India (13%), Germany (10%), and Italy (7%).

Exhibit 4: US imports USD10b worth of pharma products from India...

Source: MOFSL, oec.world


Exhibit 5: ...accounting for 13% of total imports

Source: MOFSL, oec.world

- Packaged medicaments are a part of pharma products and include medicaments in dosage, hormones (excl. contraceptives) in dosage, antibiotics in dosage, insulin in dosage, adrenal cortical hormones in dosage, alkaloid derivatives (excluding antibiotics and hormones in dosage form), vitamins, derivatives in dosage, and Penicillins and streptomycins derivatives in dosage.

Indian companies play key role in cost-saving initiatives for the US

- Generics medicines play a crucial role in the overall sustainability of the health system by providing competition in the market and lowering costs.
- Indian companies play a major role in providing these savings. Medicines from Indian companies resulted in USD219b in savings for the US healthcare system in CY22 and a total of USD1.3t during CY13-CY22 (46% of total savings).


Exhibit 6: Indian companies accounted for 52% of total saving in US market over CY18-22

Source: MOFSL, IQVIA

- Overall Indian companies have played a vital role in the stability of the health system through management of chronic and acute conditions in the US through savings for stakeholders across the system.
- From CY23 to CY27, generics are expected to provide over USD2.4t in savings, primarily from older generic medicines in mental health, hyperlipidemia, and hypertension. Indian companies are expected to continue to play a significant role in providing savings to the US healthcare system over the next five years, contributing USD1.3t in savings through the supply of generic medicines.

Indian companies have almost 50% prescription share across key therapies

- Out of the top 10 therapy areas by prescription volume, Indian companies supplied more than half of the prescriptions for five, viz. hypertension, mental health, lipid regulators, nervous system disorders, and antiulcerants.

Exhibit 7: Indian companies have the highest representation in prescription for hypertension and mental health therapies


Source: MOFSL, IQVIA

- Indian companies have the lowest representation in diabetes, respiratory and CNS medicines, which also have a lower share of generic medicines compared to the other top therapy areas.

Top 14 Indian pharma firms account for 92% of generic exports to the US


- India exports ~USD11b of pharma products to the US market, of which top 14 companies in our coverage account for ~92% of exports (USD10b).

Exhibit 8: Exports of Indian pharma companies to the US reached USD8.7b in FY24



Source: MOFSL, Pharmaexcil

Exhibit 9: US sales account for 47-48% of total sales for ARBP/ZYDUSLIF/DRRD




Source: MOFSL, oec.world

- Among large pharma companies, US sales account for ~47-48% of total sales for Aurobinod/Zyduslife/Dr. Reddy's.

Ireland/Germany/Switzerland/India top suppliers to the US

- In CY23, the US imported ~USD178b worth of pharma products, including innovative and generic products.

Exhibit 10: Top 5 suppliers account for 54% of imports




Source: MOFSL, oec.world

- In this, top 5 suppliers, viz. Ireland (18.6%), Germany (12.6%), Switzerland (10.5%), India (6.3%), and the Netherlands (5.9%), account for total 54% of imports for the US.

US is the major supply partner of India

- As of CY23, India exports pharma products worth USD23.6b to 200 countries, and the US accounts for 44% of the India's total exports (USD10.5b) of packaged medicaments.

Exhibit 11: US accounts for 44% of Indian pharma exports

Source: MOFSL, oec.world

- Over the past 23 years, India's export dependence on the US has increased multifold from USD0.67b (3% of exports) to USD10.5b (44%) in 2023.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$-10\% \text{ to } 15\%$
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA.

Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.raiani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.